Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination intravenous nutrition regimen** consisting of three separate components: - **Reconvan** (likely a commercial name for a complete or partial parenteral nutrition solution, though very limited specific data are available for this exact name in the literature; based on context and typical hospital usage, likely to be a multi-nutrient PN solution used for baseline calories, macronutrients, and micronutrients) - **Dipeptiven** (a sterile L-alanyl-L-glutamine dipeptide solution, serving as a glutamine source for critically ill or highly catabolic patients, supplementing amino acid solutions in parenteral nutrition)[9] - **Omegaven** (an intravenous fish oil–based lipid emulsion, rich in omega-3 fatty acids [EPA and DHA], indicated as a source of calories and fatty acids primarily for pediatric patients with parenteral nutrition-associated cholestasis [PNAC])[1][3][4][5] This **combination** is designed for specialized parenteral nutrition support, typically for hospitalized patients unable to tolerate or receive enteral nutrition, often in critical care or surgical settings. Mechanisms of action derive from the combined effects: - **Omegaven:** provides anti-inflammatory and immunomodulatory effects through omega-3 fatty acids, supporting liver function and reducing parenteral nutrition–associated cholestasis[1][2][3][4][5] - **Dipeptiven:** delivers glutamine, supporting protein synthesis, immune function, and gut integrity in catabolic states[9] - **Reconvan:** typically provides baseline macro- and micronutrient support (specific composition not available in provided or public sources, but standard for PN solutions)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reconvan + Dipeptiven + Omegaven.